Butler R C, Goddard D H, Higgens C S, Hollingworth P, Pease C T, Stodell M A, Scott J T
Br J Clin Pharmacol. 1985 Nov;20(5):511-3. doi: 10.1111/j.1365-2125.1985.tb05110.x.
Flurbiprofen has been compared with phenylbutazone in a double-blind study involving 33 patients with acute gout. Patients received either flurbiprofen 400 mg daily for 48 h followed by 200 mg daily, or phenylbutazone 800 mg daily for 48 h followed by 400 mg daily. The drugs were of comparable efficacy, while side-effects were uncommon and relatively mild. Flurbiprofen appears to be a satisfactory alternative to phenylbutazone in the management of acute gouty arthritis.